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Abstract The asymptomatic phase of type 1 diabetes is
recognised by the presence of beta cell autoantibodies in
the absence of hyperglycaemia. We propose that an accu-
rate description of this stage is provided by the name
‘Autoimmune Beta Cell Disorder’ (ABCD). Specifically,
we suggest that this nomenclature and diagnosis will, in a
proactive manner, shift the paradigm towards type 1 diabe-
tes being first and foremost an immune-mediated disease
and only later a metabolic disease, presaging more active
therapeutic intervention in the asymptomatic stage of dis-
ease, before end-stage beta cell failure. Furthermore, we
argue that accepting ABCD as a diagnosis will be critical
in order to accelerate pharmaceutical, academic and public
activities leading to clinical trials that could reverse beta
cell autoimmunity and halt progression to symptomatic
insulin-requiring type 1 diabetes. We recognize that there
are both opportunities and challenges in the implementation
of the ABCD concept but hope that the notion of ‘asymp-
tomatic autoimmune disease’ as a disorder will be widely
discussed and eventually accepted.
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A proposal for change
At what stage do we diagnose a disease? Do we require clin-
ical signs and symptoms or is pathology sufficient? We pres-
ent the case of asymptomatic beta cell autoimmunity in type 1
diabetes and argue for a conceptual shift in accepting this as a
diagnostic entity.
Type 1 diabetes is a frequent chronic disease in childhood
[1]. The disorder often presents acutely with metabolic decom-
pensation that, in 30% of patients, includes a degree of
ketoacidosis requiring immediate treatment and hospitalisation.
A diagnosis of type 1 diabetes places significant psychological
stress on the affected family, especially since upwards of 85%
of new cases have no family history of the disease. Patients
require life-long insulin therapy and clinical care because there
are currently limited options for restoring insulin sufficiency
and metabolic stability.
Here, we argue that type 1 diabetes should be diagnosed on
the basis of pathology, primarily as an autoimmune disease,
before it is diagnosed, classically, as a metabolic disease. The
first signs of autoimmune pathology in type 1 diabetes are not
clinically obvious, and pre-date the clinical metabolic presen-
tation resulting from end-stage autoimmune beta cell destruc-
tion. By contrast, in many other autoimmune diseases, the
clinical features and pathology are almost concomitant, such
as the swollen, painful joints in rheumatoid arthritis. In these
cases, upon the onset of symptoms, an active intervention
treatment is promptly initiated. In this paradigm, early inter-
vention means early in the course of disease and not during
end-stage disease, i.e. when the joints in rheumatoid arthritis
or the beta cells in type 1 diabetes have been destroyed.
A conceptual shift to a pathology-based diagnosis of type 1
diabetes has theoretical rigor and practical consequences.
Making the diagnosis in the asymptomatic stage, prior to clin-
ical presentation, has the potential to reduce the threat of
ketoacidosis, alleviate psychological burden, allow for earlier
initiation of experimental treatments that might preserve insu-
lin sufficiency and reduce healthcare costs.
Our insights into the pathogenesis of type 1 diabetes and
tools for detecting the onset of beta cell autoimmunity have
evolved to the point where we can now identify individuals
as ‘pre-clinical’, in whom beta cell autoimmunity will almost
inevitably result in metabolic type 1 diabetes [2].
Autoantibodies against pancreatic beta cell antigens often
develop in early childhood, precede the manifestation of
hyperglycaemia in over 90% of patients, and are now diagnos-
tic of future diabetes in children with or without a family history
of type 1 diabetes [2, 3]. Therefore, we believe there is a strong
case for recognising beta cell autoantibodies in asymptomatic
children as a true diagnosis, reflective of a medical condition
rather than just the predictive biomarker they are widely con-
sidered to represent. Moreover, while staging [3] serves the
purpose to ‘date’ a disease process, we are advocating a shift
in paradigm to type 1 diabetes being first and foremost an
immune disease and only later a metabolic disease, presaging
more active therapeutic intervention at the stage of autoimmu-
nity, before clinical diagnosis.
We propose that a paradigm shift will be achieved through
an accurate description of the autoantibody positive asymptom-
atic stage of type 1 diabetes, and that this description is provid-
ed by the name ‘autoimmune beta cell disorder’ (ABCD). This
nomenclature was introduced to us by a highly informed pa-
tient with type 1 diabetes who remarked, ‘We need a name that
indicates a pathogenic description of the stage, namely, overt
autoimmunity, with a definite therapeutic objective, namely, to
control or reverse autoimmunity’. We suggest that ABCD cor-
rectly reflects a disease that is abnormal and acquired, and if left
untreated leads to life-threatening metabolic decompensation
that requires life-long insulin therapy.
Potential arguments to retain the status quo
vs the benefits of change
A new diagnosis brings with it both opportunities and chal-
lenges. The physician must become acquainted with the new
disorder. Both the physician and the patient would require
education with regards to the benefits and risks of diagnosis,
and the guidelines for diagnosis, monitoring and clinical care.
Models for ABCD diagnosis and clinical care have been
established in clinical research settings [3] and must be
adapted for more widespread implementation. Opponents to
widespread diagnostic application of ABCD may argue that
its introduction does not yet provide a favourable cost:benefit
ratio to the individual or society. While there are clear reduc-
tions in the rates of ketoacidosis and metabolic instability at
diabetes onset in children with ABCD under clinical care [4],
the screening and monitoring costs currently outweigh the
savings in hospital care costs [5]. Currently, research funding
largely covers the costs of ABCD diagnosis and care [3, 6].
This must transition to sustainable investment from non-
research entities. An important step in this transition will be
the assignment of a proper International Statistical
Classification of Diseases and Related Health Problems
(ICD) code [7] for ABCD, the direct consequence of which
should be institutional remuneration for diagnosis and care.
The importance of having a code that reflects the autoimmune
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pathology is underscored by the fact that the type 1 diabetes
code is currently classified under endocrine, nutritional and
metabolic diseases.
Opponents [8] also routinely raise concern that around half
of children with ABCD will remain asymptomatic for months
to years and, rarely, decades, before requiring treatment for
dysglycaemia [2]. Therefore, they express concern that the life-
style of a child may be adversely affected by the diagnosis of a
condition potentially years before the appearance of symptoms.
Their concern is supported by the fact that there are currently no
treatments known to reverse ABCD that are, without question,
safe enough to administer to asymptomatic children. However,
in contrast to such opposing views, we believe that this current
inability to reverse ABCD is a crucial argument for, and benefit
of, introducing a formal diagnosis and name that recognises
this condition as a pathology. Assigning a ‘disorder’ and
‘name’ to the pre-symptomatic autoimmune stage of type 1
diabetes will fundamentally change the perception and scope
of therapeutics, from the treatment of type 1 diabetes and
hyperglycaemia to the treatment and/or prevention of ABCD.
Beyond this, colleagues opposing our notion continue to
suggest that diagnosis should wait until ABCD is manifest by
metabolic signs and, therefore, close to end-stage beta cell
failure [8]. In our opinion, this option would (by but one
example) be analogous to waiting until joints are destroyed
before attempting to treat rheumatoid arthritis. Moreover, it is
currently not feasible to screen the population metabolically
without first testing for beta cell autoantibodies and, as noted
byKnip and colleagues [8], the sensitivity of metabolic testing
for predicting clinical diabetes is still low. We are neither
adverse to including metabolic testing nor to refining it.
However, our ABCD concept calls for early diagnosis on the
basis of antibodies that, when found to be multiple and are
properly defined by biochemical assays, rarely revert [2, 9], so
that treatment to reverse the autoimmune pathology becomes
the objective. We find it concerning that to date, there have
only been four appropriately powered randomised controlled
trials of individuals with ABCD; this does not match our abil-
ity to diagnose ABCD. Even more concerning is that industry
participation in these and the currently ongoing trials is limited
to providing the study drugs. Moreover, if we listen to
critics, the field is expected to learn from trials that are mea-
sured by metabolic outcomes and performed in adults with
established metabolic disease in order to learn how to reverse
autoimmunity or ABCD in children. In contrast, we argue that
branding ABCD as a diagnosis will be a critical step in accel-
erating pharmaceutical, academic and public activities in ther-
apeutic development and clinical trials, and therapies that ef-
fectively reverse beta cell autoimmunity and halt progression
to symptomatic insulin-requiring type 1 diabetes.
Finally, introducing a diagnosis of ABCD will provide new
opportunities for paradigm-shifting research. Assuming that
health insurance providers, national medical care providers
and the pharmaceutical industry begin to cover costs associated
with the diagnosis and care of ABCD (and with clinical trials)
we could expect that research funds currently used for these
purposes could be spared and re-allocated to address more basic
research questions. In the context of prevention, these include
the identification of markers that identify treatment efficacy and
markers that guide choice of treatment, as well as the identifi-
cation of new therapeutic targets, improvement of existing can-
didate therapies and finding safe ways to combine therapies.
The path forward
We believe that the concept represented by ABCD is scientif-
ically sound and poised for clinical translation. It is likely to be
the only way forward for the prevention of type 1 diabetes. We
also suggest that the concept is not restricted to type 1 diabetes.
Rather, it could be applied to, and transform, other childhood
diseases where there are also likely benefits of pre-symptomatic
diagnosis. We recognise that there are both opportunities and
challenges to the implementation of such a concept, but hope
that with the move towards precision medicine the notion of
‘asymptomatic autoimmune disease’ as a disorder will be wide-
ly discussed and eventually accepted. Indeed, academic, indus-
trial, and public initiatives that are interested in applying preci-
sion medicine to children should consider this challenge.
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